Teresa Aldámiz‐Echevarria, Francisco Tejerina, Chiara Fanciulli, Cristina Diez, Leire Pérez, José María Bellón, Núria Espinosa, Santiago Moreno Guillen, María del Mar Arcos-Rueda, Marta Montero‐Alonso, Lucio García-Fraile, V Asensi, Marian Fernandez Lopez, Diana Corona-Mata, Alfonso Cabello-Úbeda, Meritxell Gavalda Manso, JA Iribarren, Laura Pérez‐Martínez, María Remedios Alemán Valls, Irene Portilla‐Tamarit, Joaquim Peraire, Ines Suarez-García, Mar Masiá, María José Núñez Orantos, Ángela Gutiérrez Liarte, Arkaitz Imaz, Cristina Hernández Gutiérrez, María Tasias Pitarch, Marta Rava, CoRIS Cohort
OBJECTIVES: Lymphomas remain among the most frequent HIV-associated malignancies, with risk persisting despite effective virological control. This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non-Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma-related mortality at 1 year and overall survival at 5 years. METHODS: We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV-1 RNA <100 copies/mL within the 6 months prior to and 1 month following lymphoma diagnosis. RESULTS: [IQR 202-583], p < 0.001) and more advanced Ann Arbor stage (stage III-IV: 82.0% vs. 64.1%, p = 0.027) compared with those with virological suppression. Despite this, they showed similar treatment response (complete remission: 67.1% vs. 76.2%) and relapse rates (16.3% vs. 18.4%, p = 0.779). Furthermore, virological suppression was not independently associated with 1-year lymphoma-specific or 5-year overall survival. CONCLUSIONS: In PLWH diagnosed with lymphoma, prognosis is independent of HIV virological status at diagnosis. These findings support that lymphoma management in PLWH should be guided by standard oncological criteria, alongside antiretroviral therapy, regardless of HIV viral suppression status.